Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

FHS
July 17, 2024
9:58 am

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

Cannabis Stocks Are Cheap

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter

May 8, 2023

Associations between ultra-processed food consumption and phthalate exposures in pregnant women

Researchers explored the relationship between consuming ultra-processed foods and urinary phthalate concentrations during pregnancy.

February 12, 2024

Pharma industry showers House GOP doctor with campaign cash

WASHINGTON — The pharmaceutical industry has been flooding the campaign coffers of Rep. Larry Bucshon, a cardiothoracic surgeon and Republican from Indiana, according to a STAT

August 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.